ZymoGenetics' IL-21 found to produce anti-tumor activity in skin cancer patients

By Angela McDaniels

Seattle, Nov. 14 - ZymoGenetics Inc. said its drug candidate IL-21 produced anti-tumor activity and only mild side effects in patients with advanced metastatic melanoma and renal cell carcinoma during a phase 1a clinical trial.

The primary purpose of the study was to determine a maximum tolerated dose of IL-21, and 15 patients were treated at five different dose levels, the company said.

Based on the findings, ZymoGenetics is enrolling up to 24 patients for a phase 1b study to characterize the safety of an IL-21 outpatient regimen and estimate overall response rate for each form of cancer.

The findings were presented at the International Society for Biological Therapy of Cancer annual meeting in Alexandria, Va.

ZymoGenetics is a Seattle-based biopharmaceutical company focused on the development of therapeutic proteins.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.